Show simple item record

dc.contributor.authorLitchfield, K
dc.contributor.authorStanislaw, S
dc.contributor.authorSpain, L
dc.contributor.authorGallegos, LL
dc.contributor.authorRowan, A
dc.contributor.authorSchnidrig, D
dc.contributor.authorRosenbaum, H
dc.contributor.authorHarle, A
dc.contributor.authorAu, L
dc.contributor.authorHill, SM
dc.contributor.authorTippu, Z
dc.contributor.authorThomas, J
dc.contributor.authorThompson, L
dc.contributor.authorXu, H
dc.contributor.authorHorswell, S
dc.contributor.authorBarhoumi, A
dc.contributor.authorJones, C
dc.contributor.authorLeith, KF
dc.contributor.authorBurgess, DL
dc.contributor.authorWatkins, TBK
dc.contributor.authorLim, E
dc.contributor.authorBirkbak, NJ
dc.contributor.authorLamy, P
dc.contributor.authorNordentoft, I
dc.contributor.authorDyrskjøt, L
dc.contributor.authorPickering, L
dc.contributor.authorHazell, S
dc.contributor.authorJamal-Hanjani, M
dc.contributor.authorPEACE Consortium,
dc.contributor.authorLarkin, J
dc.contributor.authorSwanton, C
dc.contributor.authorAlexander, NR
dc.contributor.authorTurajlic, S
dc.coverage.spatialUnited States
dc.date.accessioned2022-08-30T09:49:29Z
dc.date.available2022-08-30T09:49:29Z
dc.date.issued2020-05-05
dc.identifierARTN 107550
dc.identifierS2211-1247(20)30460-5
dc.identifier.citationCell Reports, 2020, 31 (5), pp. 107550 -
dc.identifier.issn2211-1247
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5344
dc.identifier.eissn2211-1247
dc.identifier.eissn2211-1247
dc.identifier.doi10.1016/j.celrep.2020.107550
dc.description.abstractAlthough thousands of solid tumors have been sequenced to date, a fundamental under-sampling bias is inherent in current methodologies. This is caused by a tissue sample input of fixed dimensions (e.g., 6 mm biopsy), which becomes grossly under-powered as tumor volume scales. Here, we demonstrate representative sequencing (Rep-Seq) as a new method to achieve unbiased tumor tissue sampling. Rep-Seq uses fixed residual tumor material, which is homogenized and subjected to next-generation sequencing. Analysis of intratumor tumor mutation burden (TMB) variability shows a high level of misclassification using current single-biopsy methods, with 20% of lung and 52% of bladder tumors having at least one biopsy with high TMB but low clonal TMB overall. Misclassification rates by contrast are reduced to 2% (lung) and 4% (bladder) when a more representative sampling methodology is used. Rep-Seq offers an improved sampling protocol for tumor profiling, with significant potential for improved clinical utility and more accurate deconvolution of clonal structure.
dc.formatPrint
dc.format.extent107550 -
dc.languageeng
dc.language.isoeng
dc.publisherCELL PRESS
dc.relation.ispartofCell Reports
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectbiomarkers
dc.subjecthomogenization
dc.subjectmolecular profiling
dc.subjectrepresentative sampling
dc.subjecttumor hetereogeneity
dc.subjecttumor mutational burden
dc.subjecttumor sampling
dc.subjecttumor sequencing
dc.subjectBiomarkers, Tumor
dc.subjectBiopsy
dc.subjectHigh-Throughput Nucleotide Sequencing
dc.subjectHumans
dc.subjectLung Neoplasms
dc.subjectMutation
dc.subjectTumor Burden
dc.subjectUrinary Bladder Neoplasms
dc.titleRepresentative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
dc.typeJournal Article
dcterms.dateAccepted2020-04-01
dc.date.updated2022-08-30T09:48:37Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.celrep.2020.107550
rioxxterms.licenseref.startdate2020-05-05
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/32375028
pubs.issue5
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular & Population Genetics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.organisational-group/ICR/Students/PhD and MPhil/13/14 Starting Cohort
pubs.publication-statusPublished
pubs.volume31
icr.researchteamMolec & Popul Genetics
icr.researchteamMelanoma & Kidney Cancer
dc.contributor.icrauthorLitchfield, Kevin
dc.contributor.icrauthorAu, Lewis
icr.provenanceDeposited by Mr Arek Surman on 2022-08-30. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S2211124720304605-main.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/